Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schultz, J.
Right arrow Articles by Axworthy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schultz, J.
Right arrow Articles by Axworthy, D.
[Cancer Research 60, 6663-6669, December 1, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

A Tetravalent Single-chain Antibody-Streptavidin Fusion Protein for Pretargeted Lymphoma Therapy1

Jody Schultz2, Yukang Lin, James Sanderson, Yuting Zuo, Diane Stone, Robert Mallett, Sibylle Wilbert and Donald Axworthy

NeoRx Corporation, Seattle, Washington 98119-4007

Single-chain Fv antibody fragments from the CD20-specific murine monoclonal antibody B9E9 were genetically engineered as streptavidin fusions [single-chain Fv-streptavidin (scFvSA) fusion protein] for use in pretargeted radioimmunotherapy. The scFvSA constructs were expressed as soluble, tetrameric species in the periplasm of Escherichia coli. Expression levels were affected by the order of the variable regions and the length and composition of the single-chain Fv linker. The best expressor was obtained with the variable regions in the heavy chain-light chain configuration separated by a 25-mer Gly4Ser linker. This construct produced 250–300 mg of soluble, tetrameric fusion protein per liter of fermentor culture. The fusion protein (Mr 173,600) was purified from crude lysates by iminobiotin affinity chromatography with an overall yield of about 50% and was analyzed for functionality both in vitro and in vivo. Immunoreactivity of the scFvSA fusion protein and its nanomolar affinity to CD20-positive Ramos cells were comparable with the B9E9 monoclonal antibody. The fusion protein had a biotin dissociation rate identical to recombinant streptavidin and bound an average of 3.6 biotins/molecule of a possible 4 biotins/molecule. Labeled fusion protein cleared from the blood of BALB/c mice with a ß half-life of about 16 h. In nude mice bearing Ramos xenografts, the fusion protein demonstrated sufficient tumor localization of functional streptavidin to enable efficient, tumor-specific targeting of a subsequently administered radionuclide-chelate/biotin molecule. These results suggest that large quantities of functional scFvSA can be produced for clinical testing as a therapy for non-Hodgkin’s lymphoma.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. Hu, X. Huang, C.-C. Ling, D. R. Bundle, and N.-K. V. Cheung
Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody
J. Immunol., November 1, 2009; 183(9): 5748 - 5755.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. Green, J. M. Pagel, E. R. Nemecek, Y. Lin, A. Kenoyer, A. Pantelias, D. K. Hamlin, D. S. Wilbur, D. R. Fisher, J. G. Rajendran, et al.
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
Blood, August 6, 2009; 114(6): 1226 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, N. Orgun, D. K. Hamlin, D. S. Wilbur, T. A. Gooley, A. K. Gopal, S. I. Park, D. J. Green, Y. Lin, and O. W. Press
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
Blood, May 14, 2009; 113(20): 4903 - 4913.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 657 - 667.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Green, J. M. Pagel, A. Pantelias, N. Hedin, Y. Lin, D. S. Wilbur, A. Gopal, D. K. Hamlin, and O. W. Press
Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Clin. Cancer Res., September 15, 2007; 13(18): 5598s - 5603s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Pantelias, J. M. Pagel, N. Hedin, L. Saganic, S. Wilbur, D. K. Hamlin, D. S. Wilbur, Y. Lin, D. Stone, D. Axworthy, et al.
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
Blood, June 1, 2007; 109(11): 4980 - 4987.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, Y. Lin, N. Hedin, A. Pantelias, D. Axworthy, D. Stone, D. K. Hamlin, D. S. Wilbur, and O. W. Press
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
Blood, July 1, 2006; 108(1): 328 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lin, J. M. Pagel, D. Axworthy, A. Pantelias, N. Hedin, and O. W. Press
A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies.
Cancer Res., April 1, 2006; 66(7): 3884 - 3892.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. J. Forster, E. B. Santos, P. M. Smith-Jones, P. Zanzonico, and S. M. Larson
Pretargeted Radioimmunotherapy with a Single-Chain Antibody/Streptavidin Construct and Radiolabeled DOTA-Biotin: Strategies for Reduction of the Renal Dose
J. Nucl. Med., January 1, 2006; 47(1): 140 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Buchsbaum, M.B. Khazaeli, D. B. Axworthy, J. Schultz, T. R. Chaudhuri, K. R. Zinn, M. Carpenter, and A. F. LoBuglio
Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein
Clin. Cancer Res., November 15, 2005; 11(22): 8180 - 8185.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Sato, R. Hassan, D. B. Axworthy, K. J. Wong, S. Yu, L. J. Theodore, Y. Lin, L. Park, M. W. Brechbiel, I. Pastan, et al.
Pretargeted Radioimmunotherapy of Mesothelin-Expressing Cancer Using a Tetravalent Single-Chain Fv-Streptavidin Fusion Protein
J. Nucl. Med., July 1, 2005; 46(7): 1201 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Forero, P. L. Weiden, J. M. Vose, S. J. Knox, A. F. LoBuglio, J. Hankins, M. L. Goris, V. J. Picozzi, D. B. Axworthy, H. B. Breitz, et al.
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Blood, July 1, 2004; 104(1): 227 - 236.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Savage, L. Gao, K. Vento, P. Cowburn, S. Man, N. Steven, G. Ogg, A. McMichael, A. Epenetos, E. Goulmy, et al.
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen
Blood, June 15, 2004; 103(12): 4613 - 4615.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N.-K. V. Cheung, S. Modak, Y. Lin, H. Guo, P. Zanzonico, J. Chung, Y. Zuo, J. Sanderson, S. Wilbert, L. J. Theodore, et al.
Single-Chain Fv-Streptavidin Substantially Improved Therapeutic Index in Multistep Targeting Directed at Disialoganglioside GD2
J. Nucl. Med., May 1, 2004; 45(5): 867 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, et al.
Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
Clin. Cancer Res., May 1, 2004; 10(9): 3137 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Stebbing, B. Gazzard, S. Patterson, M. Bower, D. Perumal, M. Nelson, A. McMichael, G. Ogg, A. Epenetos, F. Gotch, et al.
Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination
Blood, March 1, 2004; 103(5): 1791 - 1795.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. S. Graves, E. Dearstyne, Y. Lin, Y. Zuo, J. Sanderson, J. Schultz, A. Pantalias, D. Gray, D. Axworthy, H. M. Jones, et al.
Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy
Clin. Cancer Res., September 1, 2003; 9(10): 3712 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, N. Hedin, K. Subbiah, D. Meyer, R. Mallet, D. Axworthy, L. J. Theodore, D. S. Wilbur, D. C. Matthews, and O. W. Press
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
Blood, March 15, 2003; 101(6): 2340 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
O. C. Boerman, F. G. van Schaijk, W. J.G. Oyen, and F. H.M. Corstens
Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
J. Nucl. Med., March 1, 2003; 44(3): 400 - 411.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Subbiah, D. K. Hamlin, J. M. Pagel, D. S. Wilbur, D. L. Meyer, D. B. Axworthy, R. W. Mallett, L. J. Theodore, P. S. Stayton, and O. W. Press
Comparison of Immunoscintigraphy, Efficacy, and Toxicity of Conventional and Pretargeted Radioimmunotherapy in CD20-Expressing Human Lymphoma Xenografts
J. Nucl. Med., March 1, 2003; 44(3): 437 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Zhang, Z. Zhang, K. Garmestani, J. Schultz, D. B. Axworthy, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
PNAS, February 18, 2003; 100(4): 1891 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. H. Laitinen, H. R. Nordlund, V. P. Hytonen, S. T. H. Uotila, A. T. Marttila, J. Savolainen, K. J. Airenne, O. Livnah, E. A. Bayer, M. Wilchek, et al.
Rational Design of an Active Avidin Monomer
J. Biol. Chem., January 31, 2003; 278(6): 4010 - 4014.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Zhang, Z. Yao, K. Garmestani, D. B. Axworthy, Z. Zhang, R. W. Mallett, L. J. Theodore, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, et al.
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213
Blood, June 17, 2002; 100(1): 208 - 216.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, M. Corcoran, K. Subbiah, D. K. Hamlin, D. S. Wilbur, T. Johnson, L. Theodore, E. Yau, R. Mallett, D. L. Meyer, et al.
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
Blood, October 15, 2001; 98(8): 2535 - 2543.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology, January 1, 2001; 2001(1): 221 - 240.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.